RT Journal Article
SR Electronic
T1 Building a Vertically-Integrated Genomic Learning Health System: The Colorado Center for Personalized Medicine Biobank
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.09.22276222
DO 10.1101/2022.06.09.22276222
A1 Wiley, Laura K
A1 Shortt, Jonathan A
A1 Roberts, Emily R
A1 Lowery, Jan
A1 Kudron, Elizabeth
A1 Lin, Meng
A1 Mayer, David A
A1 Wilson, Melissa P
A1 Brunetti, Tonya M
A1 Chavan, Sameer
A1 Phang, Tzu L
A1 Pozdeyev, Nikita
A1 Lesny, Joseph
A1 Wicks, Stephen J
A1 Moore, Ethan
A1 Morgenstern, Joshua L
A1 Roff, Alanna N
A1 Shalowitz, Elise L
A1 Stewart, Adrian
A1 Williams, Cole
A1 Edelmann, Michelle N
A1 Hull, Madelyne
A1 Patton, J. Tacker
A1 Axell, Lisen
A1 Ku, Lisa
A1 Lee, Yee Ming
A1 Jirikowic, Jean
A1 Tanaka, Anna
A1 Todd, Emily
A1 White, Sarah
A1 Peterson, Brett
A1 Hearst, Emily
A1 Zane, Richard
A1 Greene, Casey S
A1 Mathias, Rasika
A1 Coors, Marilyn
A1 Taylor, Matthew RG
A1 Kahn, Michael G
A1 Brooks, Ian M
A1 Aquilante, Christina L
A1 Kao, David
A1 Rafaels, Nicholas
A1 Crooks, Kristy
A1 Hess, Steve
A1 Barnes, Kathleen C
A1 Gignoux, Christopher R
A1 the Colorado Center for Personalized Medicine
YR 2022
UL http://medrxiv.org/content/early/2022/06/14/2022.06.09.22276222.abstract
AB Precision medicine initiatives across the globe have led to a revolution of repositories linking large-scale genomic data with electronic health records, enabling genomic analyses across the entire phenome. Many of these initiatives focus solely on research insights, leading to limited direct benefit to patients. We describe the Biobank at the Colorado Center for Personalized Medicine (CCPM Biobank) that was jointly developed by the University of Colorado Anschutz Medical Campus and UCHealth to serve as a unique, dual-purpose research and clinical resource accelerating personalized medicine. This living resource currently has over 200,000 patients with ongoing recruitment. We highlight the clinical, laboratory, regulatory, and HIPAA-compliant informatics infrastructure along with our stakeholder engagement, consent, recontact, and participant engagement strategies. We characterize aspects of genetic and geographic diversity unique to the Rocky Mountain Region, the primary catchment area for CCPM Biobank participants. We leverage linked health and demographic information of the CCPM Biobank participant population to demonstrate the utility of the CCPM Biobank to replicate complex trait associations in the first 33,674 genotyped patients across multiple disease domains. Finally, we describe our current efforts towards return of clinical genetic test results including high-impact pathogenic variants and pharmacogenetic information, and our broader goals as the CCPM Biobank continues to grow. Bringing clinical and research interests together fosters unique clinical and translational questions that can be addressed from the large EHR-linked CCPM Biobank resource within a HIPAA and CLIA-certified environment.Competing Interest StatementKCB owns stock in, and is a part-time employee of Tempus. CRG owns stock in 23andMe, Inc. All other authors declare no relevant conflicts of interest. Funding StatementML and CRG were partially supported by the National Institutes of Health (R01HL151152, R01HG011345, and U01HG011715). KCB was partially supported by the Department Endowed Chair of Medicine, National Institutes of Health (R01AI132476, R01HL104608, R25HL146166, 5UM1AI109565-07, 5U19 AI117673-05) and Regeneron Pharmaceuticals, Inc. (Project #4841-4450-1168.2). LKW was partially supported by the National Institutes of Health (K01LM013088). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Colorado Multiple Institutional Review Board (COMIRB) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.